Key result
Atrial natriuretic peptide exerts nephroprotective effects through its antioxidant and anti-inflammatory properties, offering potential therapeutic benefits against acute and chronic kidney diseases.
ANP exhibits significant nephroprotective properties, suggesting that therapies enhancing its levels, such as ARNIs, may offer renal benefits beyond their established role in heart failure.
Answers are grounded in this paper and cite their sources.
ANP nephroprotection remains hypothesis-generating; dedicated RCTs needed before any renal application beyond heart failure.
Atrial natriuretic peptide belongs to the family of natriuretic peptides, a system with natriuretic, diuretic, and vasodilator effects that opposes to renin-angiotensin system. In addition to its classic actions, atrial natriuretic peptide exerts a nephroprotective effect given its antioxidant and anti-inflammatory properties, turning it as a beneficial agent against acute and chronic kidney diseases. This minireview describes the most relevant aspects of atrial natriuretic peptide in the kidney, including its renal synthesis, physiological actions through specific receptors, the importance of its metabolism, and its potential use in different pathological scenarios.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2021) conducted a review in Acute and chronic kidney diseases. Atrial natriuretic peptide (ANP) was evaluated. Atrial natriuretic peptide exerts nephroprotective effects through its antioxidant and anti-inflammatory properties, offering potential therapeutic benefits against acute and chronic kidney diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: